Glaukos Corporation (NYSE:GKOS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday.

According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “

Several other equities research analysts have also recently commented on the stock. BidaskClub cut shares of Glaukos Corporation from a “hold” rating to a “sell” rating in a research report on Saturday. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Glaukos Corporation in a research report on Thursday. Roth Capital cut their price objective on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday. Stephens raised shares of Glaukos Corporation from an “equal weight” rating to an “overweight” rating in a research report on Monday, May 8th. Finally, TheStreet cut shares of Glaukos Corporation from a “c” rating to a “d+” rating in a research report on Wednesday, May 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $52.33.

Glaukos Corporation (NYSE:GKOS) traded up 3.20% during trading on Monday, hitting $37.42. 435,864 shares of the stock were exchanged. The stock has a 50 day moving average price of $41.36 and a 200-day moving average price of $43.37. The firm’s market capitalization is $1.29 billion. Glaukos Corporation has a 12-month low of $28.26 and a 12-month high of $52.49.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Lowers Glaukos Corporation (GKOS) to Hold” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/zacks-investment-research-lowers-glaukos-corporation-gkos-to-hold.html.

A number of large investors have recently modified their holdings of the stock. Versant Venture Management LLC raised its stake in shares of Glaukos Corporation by 918.9% in the fourth quarter. Versant Venture Management LLC now owns 32,016,637 shares of the medical instruments supplier’s stock valued at $77,581,000 after buying an additional 28,874,420 shares during the last quarter. Frazier Management LLC acquired a new stake in shares of Glaukos Corporation during the fourth quarter valued at about $64,277,000. William Blair Investment Management LLC raised its stake in shares of Glaukos Corporation by 4.9% in the second quarter. William Blair Investment Management LLC now owns 2,164,764 shares of the medical instruments supplier’s stock valued at $89,773,000 after buying an additional 100,320 shares during the last quarter. Janus Capital Management LLC raised its stake in shares of Glaukos Corporation by 88.5% in the first quarter. Janus Capital Management LLC now owns 1,765,069 shares of the medical instruments supplier’s stock valued at $90,545,000 after buying an additional 828,567 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Glaukos Corporation by 17.6% in the first quarter. Vanguard Group Inc. now owns 1,612,838 shares of the medical instruments supplier’s stock valued at $82,739,000 after buying an additional 241,772 shares during the last quarter. Hedge funds and other institutional investors own 89.63% of the company’s stock.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Get a free copy of the Zacks research report on Glaukos Corporation (GKOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.